Olenza

Olanzapine

Acute & maintenance treatment of schizophrenia & other psychoses where +ve &/or -ve symptoms are prominent. Alleviates secondary affective symptoms commonly associated w/ schizophrenia & related disorders. Short-term treatment of acute manic episode associated w/ bipolar I disorder. Preventing recurrence of manic, mixed or depressive episodes in bipolar I disorder.

Schizophrenia Initially 10 mg daily. Manic episode Monotherapy: Initially 15 mg single daily dose. Combination therapy: Initially 10 mg daily. Preventing recurrence in bipolar disorder Initially 10 mg daily. Schizophrenia, manic episode & recurrence prevention in bipolar disorder Dose range: 5-20 mg daily. Renal &/or hepatic impairment Initially 5 mg daily.

May be taken with or without food.

Hypersensitivity. Narrow-angle glaucoma.

Discontinue use if drug reaction w/ eosinophilia & systemic symptoms is suspected. Hyperglycemia & DM; dementia-related psychosis &/or behavioral disturbances; Parkinson's disease; neuroleptic malignant syndrome; prostatic hypertrophy, paralytic ileus; neutropenia, history of drug-induced bone marrow depression/toxicity, bone marrow depression caused by concomitant illness, radiation or chemotherapy, hypereosinophilic conditions, myeloproliferative disease; congenital long QT syndrome, CHF, heart hypertrophy, hypokalaemia, hypomagnesaemia; venous thromboembolism; history of seizures; tardive dyskinesia; postural hypotension. Monitor lipid levels regularly. Elevated ALT &/or AST, preexisting conditions associated w/ limited hepatic functional reserve. Avoid abrupt discontinuation. Concomitant use w/ potentially hepatotoxic drugs, drugs known to increase QTc interval, other centrally-acting medicines & alcohol. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Moderate hepatic insufficiency (cirrhosis, Child-Pugh class A or B). Pregnancy & lactation. Not recommended in childn & adolescents <18 yr. Elderly ≥65 yr.

Somnolence, wt gain, eosinophilia; elevated prolactin, cholesterol, glucose & triglyceride levels; glucosuria, increased appetite, dizziness, akathisia, parkinsonism, dyskinesia, orthostatic hypotenslon, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases, rash, asthenia, fatigue, oedema.

Induced metabolism by smoking, carbamazepine. Inhibited metabolism by fluvoxamine, ciprofloxacin, ketoconazole. Reduced bioavailability by activated charcoal. Antagonized effects of direct & indirect dopamine agonists.

Antipsychotics

N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics

B